Century Therapeutics (IPSC) Total Liabilities (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Total Liabilities data on file, last reported at $61.8 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $61.8 million, down 17.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.8 million (down 17.77% YoY), and the FY2025 annual result was $64.8 million, down 66.24% from the prior year.
• Total Liabilities declined to $61.8 million in Q1 2026 per IPSC's latest filing, from $64.8 million in the prior quarter.
• Over five years, Total Liabilities peaked at $194.3 million in Q2 2024 and troughed at $61.8 million in Q1 2026.
• A 5-year average of $147.1 million and a median of $174.6 million in 2022 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities surged 346.81% in 2022, then sank 66.24% in 2025.
• A 5-year view of Total Liabilities shows it stood at $183.8 million in 2022, then declined by 4.28% to $175.9 million in 2023, then advanced by 9.04% to $191.9 million in 2024, then slumped by 66.24% to $64.8 million in 2025, then fell by 4.57% to $61.8 million in 2026.
• Business Quant data shows IPSC's Total Liabilities at $61.8 million in Q1 2026, $64.8 million in Q4 2025, and $68.4 million in Q3 2025.